|
| |
BioPortfolio's Approved Drugs DatabaseEnbrelEtanerceptDownload PDF containing detailed information.
Press Releases About Enbrel:
|
 |
| Stelara is Expected to Substantially Alter Patient Flow to TNF-Alpha Inhibitors Prescribed for Psoriasis Over the Next Two Years |
11th November, 2009 |
Decision Resources |
WALTHAM, Mass., Nov. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor
|
| Biosimilars of TNF-alpha Inhibitors Stand to Erode Over $9 Billion in Brand Sales in the U.S. and Europe by 2018 |
3rd November, 2009 |
Decision Resources |
WALTHAM, Mass., Nov. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor
|
| Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roche's Actemra for Rheumatoid Arthritis |
2nd November, 2009 |
Decision Resources |
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed
|
| Cephalon Appoints Bob Repella as Senior Vice President of U.S. Pharmaceutical Operations |
27th October, 2009 |
Cephalon, Inc. |
FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Bob Repella has joined as Senior Vice President, U.S Pharmaceutical Operations. In this role, Mr.
|
| Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market |
26th October, 2009 |
Decision Resources |
WALTHAM, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of
|
Companies working in the area of Enbrel from Bioportfolio's Biocorporate database : | |
| Company Name | |
Enbrel® (etanercept) is a TNF inhibitor approved for the following indications: moderately to severely active rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic...
www.enbrel.com View full profile
| |
ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as...
www.enbrel.com/ View full profile
| |
VLST Corporation discovers and develops novel therapeutics for the treatment of inflammatory and autoimmune diseases. Disease areas in which the company’s technology may have utility include multiple...
www.vlstcorp.com/ View full profile
| | →View more Enbrel related companies. |
This page has been viewed 52 times
Recent Search Terms used to find this page: .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Enbrel across BioPortfolio, or for Enbrel Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
